Cancer involves complex etiology factors, multiple stages, and intricate gene mutations.
Long non-coding RNAs (lncRNAs) are implicated as molecular mechanisms underlying …

Immune infiltration of tumors has been increasingly accepted as a prognostic factor in colon
cancer. Here, we aim to develop a novel immune signature, based on estimated immune …

Mutations in KRAS are among the most frequent aberrations in cancer, including colon
cancer. KRAS direct targeting is daunting due to KRAS protein resistance to small molecule …

Background Mutation status of RAS and BRAF, as well as serum levels of carcinoembryonic
antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9), are biomarkers used in clinical …

Background Intratumoural T-cell infiltrate intensity cortes wrelaith clinical outcome in stage
II/III colorectal cancer (CRC). We aimed to determine whether this association varies across …

Background Programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) play a pivotal role in cancer immunotherapy. Each of these …

Purpose Microsatellite instability (MSI) due to mismatch repair (MMR) defects accounts for
15–20% of colon cancers (CC). MSI testing is currently standard of care in CC with …

Background and Aims The heterogeneity among colorectal tumors is probably due to
differences in developmental pathways and might associate with patient survival times. We …

(KRAS, NRAS, and HRAS), KRAS is most commonly mutated in pancreatic, colorectal, and
lung adenocarcinomas, whereas NRAS and HRAS mutations are mostly found in selected …

The use of biomarkers that influence a targeted choice in cancer treatments is the future of
medical oncology. Within this scenario, in recent years, an important role has been played …